Showing results (21-30 of 53) with videos related to
Sort By:
Pageof 6
Biochimica Et Biophysica Acta|July 27, 2010
Non-lipolytic and lipolytic sequence-related carboxylesterases: a comparative study of the structure-function relationships of rabbit liver esterase 1 and bovine pancreatic bile-salt-activated lipaseHenri Chahinian, Jacques Fantini, Nicolas Garmy, et al.Viruses|September 28, 2023
Host Membranes as Drivers of Virus EvolutionMélanie Matveeva, Marine Lefebvre, Henri Chahinian, et al.International Journal of Molecular Sciences|January 21, 2023
AmyP53 Prevents the Formation of Neurotoxic β-Amyloid Oligomers through an Unprecedent Mechanism of Interaction with Gangliosides: Insights for Alzheimer's Disease TherapyFodil Azzaz, Henri Chahinian, Nouara Yahi, et al.Biochemistry|July 8, 2014
Interaction of Alzheimer's β-amyloid peptides with cholesterol: mechanistic insights into amyloid pore formationCoralie Di Scala, Henri Chahinian, Nouara Yahi, et al.Advances in Protein Chemistry and Structural Biology|January 17, 2022
Ganglioside binding domains in proteins: Physiological and pathological mechanismsFodil Azzaz, Nouara Yahi, Coralie Di Scala, et al.Biomolecules|May 24, 2018
Anandamide Revisited: How Cholesterol and Ceramides Control Receptor-Dependent and Receptor-Independent Signal Transmission Pathways of a Lipid NeurotransmitterCoralie Di Scala, Jacques Fantini, Nouara Yahi, et al.Molecules (Basel, Switzerland)|June 24, 2022
Structural Dynamics of the SARS-CoV-2 Spike Protein: A 2-Year Retrospective Analysis of SARS-CoV-2 Variants (from Alpha to Omicron) Reveals an Early Divergence between Conserved and Variable EpitopesPatrick Guérin, Nouara Yahi, Fodil Azzaz, et al.International Journal of Molecular Sciences|November 11, 2022
AmyP53, a Therapeutic Peptide Candidate for the Treatment of Alzheimer's and Parkinson's Disease: Safety, Stability, Pharmacokinetics Parameters and Nose-to Brain DeliveryCoralie Di Scala, Nicholas Armstrong, Henri Chahinian, et al.Pharmacology & Therapeutics|January 19, 2025
Conformationally adaptive therapeutic peptides for diseases caused by intrinsically disordered proteins (IDPs). New paradigm for drug discovery: Target the target, not the arrowJacques Fantini, Fodil Azzaz, Coralie Di Scala, et al.Journal of Molecular Biology|February 2, 2010
Altered ion channel formation by the Parkinson's-disease-linked E46K mutant of alpha-synuclein is corrected by GM3 but not by GM1 gangliosidesEric Di Pasquale, Jacques Fantini, Henri Chahinian, et al.Pageof 6